乳腺癌组织中c-erbB-2、p53和PCNA的表达及与预后因素的关系

Expression of c-erbB-2,p53 and proliferating cell nuclear antigen in breast cancer and its relationship with prognosis

目的探讨生物学指标c-erbB-2、p53和增殖细胞核抗原(PCNA)在乳腺癌中的表达及与临床乳腺癌预后因素的关系。方法应用免疫组织化学方法对1180例乳腺癌组织切片c-erbB-2、p53、PCNA的表达进行检测。结果c-erbB-2表达与患者年龄(≥35岁)、临床期别、腋淋巴结状态、组织学分级呈负相关,与ER、PR受体呈正相关;p53蛋白的表达与患者的临床期别、组织学分级、病理类型呈负相关,与腋淋巴结状态呈正相关;PCNA的表达与患者的临床期别、腋淋巴结状况呈负相关,与ER、PR呈正相关。结论生物学指标c-erbB-2、p53、PCNA应与临床预后因素临床期别、组织学分级、腋淋巴结状态及病理类型等联合应用,有助于提高对乳腺癌预后评价的正确性。

Objective To detect the correlation between the expression of e - erbB - 2, p53 and proliferating cell nuclear antigen （PCNA） in breast cancer and its relationship with prognosis. Methods Expression of four biomarkers in 1180 eases of breast cancer were determined by immunohistoehemistry. Results The expression of e - erbB - 2 was negatively correlated with age （ ≥ 35 years）, clinical stage, axillary lymph node status, histology classification, and positively related with ER, PR. p53 was negatively correlated with clinical stage, histology classification, pathologic type, and positively related with axillary lymph node sta- tus. PCNA was negatively correlated with clinical stage, axillary lymph node status, and positively related with ER, PR. Conclusions The biological markers should be considered together with clinical stage, histological degree, lymph node status and pathological type for enhancing the accuracy of prognostic evaluation in breast cancer.